Ernexa Therapeutics Inc 8-K, filed Apr 23, 2021
Ernexa Therapeutics Inc. (ERNA)
8-K
2021-04-23
For: 2021-04-21
View Original
Added on
April 06, 2026
About this 8-K
Ernexa Therapeutics Inc filed this 8-K on April 23, 2021, reporting on events of April 21, 2021.
Items reported
- Item 4.01: Change of auditor
- Item 9.01: Financial statements and exhibits
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 21, 2021
BROOKLYN IMMUNOTHERAPEUTICS, INC.
(Exact Name of Registrant as Specified in its Charter)
|
Delaware
|
001-11460
|
31-1103425
|
|
(State or Other Jurisdiction of Incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
|
140 58th Street, Building A, Suite 2100
|
||
|
Brooklyn, New York
|
11220
|
|
|
(Address of Principal Executive Offices)
|
(Zip Code)
|
Registrant’s telephone number, including area code: (212) 582-1199
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
Trading symbol
|
Name of each exchange on which registered
|
||
|
Common Stock, $0.005 par value per share
|
BTX
|
NYSE American
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934:
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 4.01 |
Changes in Registrant’s Certifying Accountant.
|
| (a) |
Dismissal of Previous Independent Registered Public Accounting Firm
|
On April 21, 2021, the audit committee of the board of directors dismissed Baker Tilly US, LLP, or Baker Tilly, as our independent registered public accounting firm. As used
below, “Baker Tilly” includes Squar Milner LLP prior to its combination with Baker Tilly US, LLP effective November 1, 2020.
The reports of Baker Tilly on our consolidated financial statements for the fiscal years ended December 31, 2020 and 2019 did not contain an adverse opinion or disclaimer of
opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles, except that each such report included an explanatory paragraph relating to our ability to continue as a going concern.
During the fiscal years ended December 31, 2020 and 2019 and in the subsequent interim period through April 21, 2021, there were (a) no “disagreements” (as defined in Item
304(a)(1)(iv) of Regulation S‑K and the related instructions) with Baker Tilly on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure that, if not resolved to the satisfaction of Baker
Tilly, would have caused Baker Tilly to make reference thereto in its reports on the consolidated financial statements for such fiscal years and (b) no “reportable events” (as defined in Item 304(a)(1)(v) of Regulation S‑K).
We provided a copy of the foregoing disclosures to Baker Tilly and requested that Baker Tilly furnish us with a letter addressed to the Securities and Exchange Commission,
pursuant to Item 304(a)(3) of Regulation S-K, stating whether or not Baker Tilly agreed with the above disclosures. A copy of Baker Tilly’s letter furnished pursuant to that request is filed as Exhibit 16.1 to this Form 8-K.
We expect the audit committee will conduct a competitive selection process to determine our independent registered public accounting firm for the fiscal year ending December
31, 2021.
| Item 9.01 |
Financial Statements and Exhibits.
|
| (d) |
Exhibit
|
|
Exhibit No.
|
Description
|
||
|
Letter dated April 23, 2021 from Baker Tilly US, LLP to the Securities and Exchange Commission
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.
|
BROOKLYN IMMUNOTHERAPEUTICS, INC.
|
||
|
Dated: April 23, 2021
|
By:
|
/s/ Howard J. Federoff
|
|
Howard J. Federoff
|
||
|
Chief Executive Officer and President
|
||
Exhibit 16.1
April 23, 2021
Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
We have read Item 4.01 of Brooklyn ImmunoTherapeutics, Inc.’s Form 8-K dated April 21, 2021. We agree with the statements made in response to that Item insofar as they relate to our Firm.
Very truly yours,
/s/ BAKER TILLY US, LLP